{"protocolSection": {"identificationModule": {"nctId": "NCT00382863", "orgStudyIdInfo": {"id": "200"}, "organization": {"fullName": "Paracor Medical, Inc", "class": "INDUSTRY"}, "briefTitle": "Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial", "officialTitle": "Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial", "acronym": "PEERLESS-HF"}, "statusModule": {"statusVerifiedDate": "2012-06", "overallStatus": "TERMINATED", "whyStopped": "Resources unavailable to continue study follow-up.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-10"}, "primaryCompletionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-09-28", "studyFirstSubmitQcDate": "2006-09-28", "studyFirstPostDateStruct": {"date": "2006-10-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-05-13", "resultsFirstSubmitQcDate": "2012-06-07", "resultsFirstPostDateStruct": {"date": "2012-07-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-06-07", "lastUpdatePostDateStruct": {"date": "2012-07-13", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Paracor Medical, Inc", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine if patients in the HeartNet Ventricular Support System with optimal medical and device therapy arm (Treatment group) show statistically significant improvement compared to patients in the optimal medical and device therapy alone arm (Control group) after 6 months of follow-up.", "detailedDescription": "In the United States alone, more than five million people suffer from heart failure (CHF) and an estimated 400,000 to 700,000 new cases are diagnosed each year. Caused by a variety of cardiac conditions, systolic heart failire (HF) is the end-stage of heart disease where the heart is failing as a pump. Once diagnosed with the disease, less than 50% of the patients live for five years, and less than 25% survive for more than ten years. The number of deaths in the United States from this condition has more than doubled since 1979, averaging more than 250,000 annually.\n\nParacor Medical, Inc. has developed an elastic prosthetic wrap that is designed to apply a gentle mechanical support to the failing heart. The Implant is a compliant elastic structure that is designed to conform to the epicardial surface of the right and left ventricles. It supports the heart throughout the cardiac cycle and was designed to offload the ventricles and reduce wall stress.\n\nThe objective of this clinical trial is to evaluate the safety and efficacy of the HeartNet Ventricular Support System with optimal medical and device therapy (Treatment group) when compared to optimal medical and device therapy (i.e., medications, cardiac resynchronisation therapy, pacemaker) alone (Control group) as treatments for patients with heart failure.\n\nEfficacy of the HeartNet Ventricular Support System in the Treatment group compared to the optimal medical and device therapy Control group will be evaluated based upon cardiopulmonary tests (Peak VO2), six (6) minute walk distance and quality of life assessment, as measured by the Minnesota Living with Heart Failure (MLWHF) questionnaire.\n\nSafety of the HeartNet Ventricular Support System in the Treatment group compared to the Control group will be evaluated based on the all-cause mortality rate.\n\nParacor Medical intends to submit data obtained in this clinical trial to support a Pre-Market Approval Application to the United States Food and Drug Administration."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["heart failure", "cardiac support", "Paracor", "HeartNet", "PEERLESS-HF"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 220, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment", "type": "EXPERIMENTAL", "description": "HeartNet and Optimal Medical/Device Therapy (e.g., medications and cardiac resynchronisation therapy)", "interventionNames": ["Device: HeartNet Ventricular Support System"]}, {"label": "Control", "type": "ACTIVE_COMPARATOR", "description": "Optimal Medical/Device Therapy alone (e.g., medications and/or cardiac resynchronisation therapy) (Note: For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of angiotensin converting enzyme (ACE) inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy-defibrillator (CRT-D) for at least three months prior to study enrollment, when indicated.)", "interventionNames": ["Drug: Optimal Medical/Device Therapy"]}], "interventions": [{"type": "DEVICE", "name": "HeartNet Ventricular Support System", "description": "The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.", "armGroupLabels": ["Treatment"], "otherNames": ["cardiac support"]}, {"type": "DRUG", "name": "Optimal Medical/Device Therapy", "description": "Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.", "armGroupLabels": ["Control"], "otherNames": ["heart failure medications"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Responder Analysis - Peak Oxygen Uptake (Peak VO2)", "description": "A participant was considered a \"responder\" if cardiopulmonary exercise testing demonstrated an improvement in peak VO2 of at least 1.0 ml/kg/min at 6 months as compared to baseline.", "timeFrame": "Baseline to 6 months"}, {"measure": "Responder Analysis - Six (6) Minute Walk (6MW) Distance", "description": "A participant was considered a \"responder\" if 6MW distance at 6 months was at least 45 meters more than at baseline.", "timeFrame": "Baseline to 6 months"}, {"measure": "Responder Analysis - Minnesota Living With Heart Failure (MLWHF) Quality of Life Overall Score", "description": "A participant was considered a \"responder\" if the MLHF overall score had improved by at least 7 points at 6 months as compared to baseline. THE MLHF questionnaire evaluates the impact of heart failure (HF) on a subject's physical, emotional, social and mental aspects of quality of life. Each of 21 questions about how much HF impacts daily activities is scored from 0-no impact to 5-very much (overall score can range from 0 to 105). Improvement is indicated by a decrease in score.", "timeFrame": "baseline to 6 months"}, {"measure": "Number of Participant Deaths", "description": "Total number of participants who died within 12 months of enrollment into the trial.", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "Change in New York Heart Association (NYHA) Functional Class", "description": "Change in NYHA functional class between baseline and 6 months. \"Maintained\" means the participant's functional class remained the same as baseline. \"Improved\" means the participant's functional class improved (became lower in number) by at least one class. \"Worsened\" means the participant's functional class deteriorated (became higher in number) by at least one class.", "timeFrame": "baseline to 6 months"}, {"measure": "Change in Quality of Life as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)", "description": "The KCCQ is a 23-item questionnaire that quantifies physical function, symptoms, social function, self-efficacy/knowledge and quality of life. Scores range from 0 to 100, where higher scores reflect better health status. For this outcome measure, the difference between each participant's baseline and 6-month KCCQ scores was calculated. The mean change for each treatment arm is presented.", "timeFrame": "baseline to 6 months"}, {"measure": "Change in Left Ventricular Mass", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular mass was calculated. The median change for each treatment arm is presented. A decrease in mass is associated with an improvement in the participant's structural heart failure.", "timeFrame": "baseline to 6 months"}, {"measure": "Responder Analysis - Peak Oxygen Uptake (Peak VO2)", "description": "A participant was considered a \"responder\" if cardiopulmonary exercise testing demonstrated an improvement in peak VO2 of at least 1.0 ml/kg/min at 12 months as compared to baseline.", "timeFrame": "baseline to 12 months"}, {"measure": "Responder Analysis - Six (6) Minute Walk (6MW) Distance", "description": "A participant was considered a \"responder\" if 6MW distance at 12 months was at least 45 meters more than at baseline.", "timeFrame": "baseline to 12 Months"}, {"measure": "Responder Analysis - Minnesota Living With Heart Failure (MLWHF) Quality of Life Overall Score", "description": "A participant was considered a \"responder\" if the MLHF overall score had improved by at least 7 points at 12 months as compared to baseline. THE MLHF questionnaire evaluates the impact of heart failure (HF) on a subject's physical, emotional, social and mental aspects of quality of life. Each of 21 questions about how much HF impacts daily activities is scored from 0-no impact to 5-very much (overall score can range from 0 to 105). Improvement is indicated by a decrease in score.", "timeFrame": "baseline to 12 months"}, {"measure": "Heart Failure Hospitalization - Actuarial Analysis", "description": "Kaplan-Meier actuarial analysis of heart failure hospitalization (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment", "timeFrame": "12 months"}, {"measure": "Change in Left Ventricular End Diastolic Volume", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end diastolic volume was calculated. The median change for each treatment arm is presented. A decrease in volume is associated with an improvement in the participant's structural heart failure.", "timeFrame": "baseline to 6 months"}, {"measure": "Change in Left Ventricular End Systolic Volume", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end systolic volume was calculated. The median change for each treatment arm is presented. A decrease in volume indicates an improvement in the participant's structural heart failure.", "timeFrame": "baseline to 6 months"}, {"measure": "Change in Ejection Fraction", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular ejection fraction was calculated. The median change for each treatment arm is presented.", "timeFrame": "baseline to 6 months"}, {"measure": "Change in Left Ventricular End Diastolic Diameter", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end diastolic diameter was calculated. The median change for each treatment arm is presented. A decrease in diameter indicates an improvement in the participant's structural heart failure.", "timeFrame": "baseline to 6 months"}, {"measure": "Change in Left Ventricular End Systolic Diameter", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end systolic diameter was calculated. The median change for each treatment arm is presented. A decrease in diameter indicates an improvement in the participant's structural heart failure.", "timeFrame": "baseline to 6 months"}, {"measure": "Technical Success (Number of Treatment Arm Participants Successfully Implanted)", "description": "\"Technical success\" refers to the ability to successfully deliver a device onto the epicardial surface and leave the device in a satisfactory position. Participants who did not undergo an implant procedure were excluded from this analysis.", "timeFrame": "1 day"}, {"measure": "Heart Failure Death", "description": "Number of participants who died within 12 months of enrolling in the study and whose cause of death was classified, by an independent Clinical Events Committee, as heart failure", "timeFrame": "12 months"}, {"measure": "Heart Failure Death - Actuarial Analysis", "description": "Kaplan-Meier actuarial time-to-event analysis of deaths classified, by an independent Clinical Events Committee, as due to heart failure", "timeFrame": "12 months"}, {"measure": "Heart Failure Hospitalization", "description": "Number of participants who experienced a heart failure hospitaliz (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment.", "timeFrame": "12 months"}, {"measure": "All-Cause Hospitalization", "description": "Number of participants who experienced a hospitalization (for any cause) within the first 12 months after enrollment. Within the Treatment Arm, hospitalization for the implant procedure was not included in this analysis.", "timeFrame": "12 months"}, {"measure": "All-Cause Hospitalization - Actuarial Analysis", "description": "Kaplan-Meier actuarial time-to-first-event analysis of all-cause hospitalizations", "timeFrame": "12 months"}, {"measure": "Participants Experiencing Serious Adverse Events", "description": "Number of participants who experienced a serious adverse event (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment", "timeFrame": "12 months"}, {"measure": "Serious Adverse Events - Actuarial Analysis", "description": "Kaplan-Meier actuarial time-to-first-event analysis of serious adverse events", "timeFrame": "12 months"}, {"measure": "Days Alive Out of Hospital", "description": "Median number of days participants were not hospitalized within the first 12 months after enrollment. Within the Treatment Arm, hospitalization for the implant procedure was not included in this analysis.", "timeFrame": "12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Symptomatic heart failure at enrollment (American College of Cardiology \\[ACC\\]/American Heart Association \\[AHA\\] Stage C) due to ischemic or nonischemic dilated cardiomyopathy\n2. On stable, evidence-based medical and device therapy for heart failure for 3 months prior to randomization \\<a\\> Pharmacological Therapy (as appropriate) \\<i\\> angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) for patients with ACE inhibitor intolerance or nitrate/hydralazine at the investigators discretion \\<ii\\> beta blockers \\<iii\\> diuretics, aldosterone inhibitors \\<b\\> Ejection fraction \\< or = to 35% while maintained on optimal medical therapy \\<c\\> Cardiac Resynchronization Therapy (CRT), Cardiac Resynchronization Therapy-Defibrillator (CRT-D) \\<i\\> If implanted with a CRT or CRT-D, it must be implanted \\> or = to 3 months before randomization \\<ii\\> If currently eligible or anticipated eligibility with a CRT or CRT-D within 6 months, the patient should not be enrolled in the study\n\nSpecific Qualifying Characteristics\n\n1. Six (6) minute walk of 150 - 450m\n2. Peak VO2 for males: 10.0-20.0 ml/kg/min; Peak VO2 for females: 9.0-18.0 ml/kg/min\n3. Left ventricular end diastolic diameter (LVEDD) \\<85mm and index \\<40mm/m2 (LVEDD/BSA)\n4. Heart failure duration \\> or = to 6 months\n\nExclusion Criteria:\n\nPatient History\n\n1. Heart failure due to a reversible condition\n2. Hypertrophic obstructive cardiomyopathy (HOCM)\n3. Left ventricular assist device (LVAD), intra-aortic balloon pump (IABP) or intravenous inotropes are required or the patient has end stage heart failure despite maintenance on best medical therapy\n4. Myxoma\n5. Active infection, sepsis, endocarditis, myocarditis or pericarditis\n6. Myocardial infarction, stroke, transient ischemic attack, cardiac or other major surgery, or implantable cardioverter defibrillator (ICD) or pacemaker implantation in the 3 months prior to entry\n7. Positive pregnancy test for pre-menopausal female\n8. Less than 18 years or \\> or = to 75 years old\n9. Hemoglobin level less than 10 gm/dL or creatinine \\>2.5 mg/dL\n10. Uncontrolled medical conditions that increase surgical risk\n11. Co-morbid condition that in the investigator's opinion reduces life expectancy to less than 2 years\n\nSurgical or Anatomical Considerations\n\n1. Heart measurement too large or small for Implant sizes\n2. Restrictive cardiomyopathy\n3. Not a candidate for sternotomy or standard thoracotomy surgical approaches\n4. Expected to have adhesions from previous surgical procedures\n5. History of constrictive pericarditis\n6. Previously placed coronary artery bypass grafts (CABG) or anticipated need for coronary artery bypass grafting\n7. Not a candidate for cardiopulmonary bypass\n8. Anatomical mitral valve regurgitation of 2+ or greater at the time of enrollment\n9. Pulmonary function testing with the following results: Forced expiratory volume (FEV1) \\<1L or if FEV1 is between 1 and 3L, forced expiratory volume divided by forced vital capacity (FEV1/FVC) \\<60%\n10. Cardiac or thoracic condition that might require operative correction. Cardiac transplantation is not included in this exclusion criterion.\n11. Other elective surgical procedure at the time of the index hospitalization or within 30 days, whichever is longer\n\nOther\n\n1. Any other medical condition that, in the judgment of the investigator, makes the patient a poor candidate for this procedure\n2. Currently enrolled or has participated in the last 30 days in another therapeutic or interventional clinical study\n3. Unwilling/unable to comply with follow-up\n4. Unwilling/unable to give signed informed consent", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "74 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "William T. Abraham, MD", "affiliation": "Chief, Division of Cardiovascular Medicine, The Ohio State University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Alabama Birmingham", "city": "Birmingham", "state": "Alabama", "zip": "35294", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "USC Keck School of Medicine", "city": "Los Angeles", "state": "California", "zip": "90033", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "University of California, San Francisco, Medical Center", "city": "San Francisco", "state": "California", "zip": "94143", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "University of Colorado Health Sciences Center", "city": "Aurora", "state": "Colorado", "zip": "80045", "country": "United States", "geoPoint": {"lat": 39.72943, "lon": -104.83192}}, {"facility": "Christiana Care Health System", "city": "Newark", "state": "Delaware", "zip": "19718", "country": "United States", "geoPoint": {"lat": 39.68372, "lon": -75.74966}}, {"facility": "University of Florida", "city": "Gainesville", "state": "Florida", "zip": "32610", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Emory University", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Midwest Heart Foundation", "city": "Lombard", "state": "Illinois", "zip": "60148", "country": "United States", "geoPoint": {"lat": 41.88003, "lon": -88.00784}}, {"facility": "St. Vincent Hospital and Health Services", "city": "Indianapolis", "state": "Indiana", "zip": "46260", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Genesis Medical Center", "city": "Davenport", "state": "Iowa", "zip": "52803", "country": "United States", "geoPoint": {"lat": 41.52364, "lon": -90.57764}}, {"facility": "University of Maryland, Division of Cardiology", "city": "Baltimore", "state": "Maryland", "zip": "21201", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Caritas St. Elizabeth's Medical Center", "city": "Boston", "state": "Massachusetts", "zip": "02135", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Wayne State University/ Oakwood Hospital", "city": "Detroit", "state": "Michigan", "zip": "48201", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "Minneapolis VA Medical Center", "city": "Minneapolis", "state": "Minnesota", "zip": "55417", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "St. Paul Heart Clinic", "city": "St. Paul", "state": "Minnesota", "zip": "55102", "country": "United States", "geoPoint": {"lat": 44.94441, "lon": -93.09327}}, {"facility": "Mid America Heart Institute", "city": "Kansas City", "state": "Missouri", "zip": "64111", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "BryanLGH Heart Improvement Program", "city": "Lincoln", "state": "Nebraska", "zip": "68506", "country": "United States", "geoPoint": {"lat": 40.8, "lon": -96.66696}}, {"facility": "Morristown Memorial Hospital", "city": "Morristown", "state": "New Jersey", "zip": "07962", "country": "United States", "geoPoint": {"lat": 40.79677, "lon": -74.48154}}, {"facility": "Montefiore Medical Center", "city": "Bronx", "state": "New York", "zip": "10467", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "University of Rochester Medical Center", "city": "Rochester", "state": "New York", "zip": "14642", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "The Lindner Clinical Trial Center", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "The Ohio State University Medical Center", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Oklahoma Heart Hospital", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Penn State Milton S. Hershey Medical Center", "city": "Hershey", "state": "Pennsylvania", "zip": "17033", "country": "United States", "geoPoint": {"lat": 40.28592, "lon": -76.65025}}, {"facility": "Allegheny General Hospital", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15212", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "The Stern Cardiovascular Center", "city": "Germantown", "state": "Tennessee", "zip": "38138", "country": "United States", "geoPoint": {"lat": 35.08676, "lon": -89.81009}}, {"facility": "Tennessee Cardiovascular Research Institute", "city": "Nashville", "state": "Tennessee", "zip": "37205", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Intermountain Medical Center", "city": "Murray", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "Inova Heart & Vascular Institute/ Fairfax Hospital", "city": "Falls Church", "state": "Virginia", "zip": "22042", "country": "United States", "geoPoint": {"lat": 38.88233, "lon": -77.17109}}, {"facility": "University of Calgary", "city": "Calgary", "state": "Alberta", "zip": "T2N 4N1", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "St. Paul's Hospital", "city": "Vancouver", "state": "British Columbia", "zip": "V6Z 1Y6", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "St. Boniface General Hospital", "city": "Winnipeg", "state": "Manitoba", "zip": "R2H 2A6", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "London Health Sciences Centre", "city": "London", "state": "Ontario", "zip": "N6A 5A5", "country": "Canada", "geoPoint": {"lat": 42.98339, "lon": -81.23304}}, {"facility": "Toronto General Hospital", "city": "Toronto", "state": "Ontario", "zip": "M5G 2C4", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "McGill University Hospital Centre", "city": "Montreal", "state": "Quebec", "zip": "H3A 1A1", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}]}, "referencesModule": {"references": [{"pmid": "23137493", "type": "DERIVED", "citation": "Abraham WT, Anand I, Aranda JM Jr, Boehmer J, Costanzo MR, DeMarco T, Holcomb R, Ivanhoe R, Kolber M, Rayburn B. Randomized controlled trial of ventricular elastic support therapy in the treatment of symptomatic heart failure: rationale and design. Am Heart J. 2012 Nov;164(5):638-45. doi: 10.1016/j.ahj.2012.07.015. Epub 2012 Oct 2."}, {"pmid": "20522572", "type": "DERIVED", "citation": "Keteyian SJ, Brawner CA, Ehrman JK, Ivanhoe R, Boehmer JP, Abraham WT; PEERLESS-HF Trial Investigators. Reproducibility of peak oxygen uptake and other cardiopulmonary exercise parameters: implications for clinical trials and clinical practice. Chest. 2010 Oct;138(4):950-5. doi: 10.1378/chest.09-2624. Epub 2010 Jun 3."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "3 subjects were considered Roll-in (not randomized) and received treatment. Data from these subjects are not included in the results. Seven (7) subjects were randomized to the Treatment group but were not treated due to suspension of the study. These subjects are excluded from the data.", "recruitmentDetails": "Subjects were recruited from 29 investigational sites in the US and 6 investigational sites in Canada, between November, 2006 to September, 2009", "groups": [{"id": "FG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "FG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "96"}, {"groupId": "FG001", "numSubjects": "114"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "81"}, {"groupId": "FG001", "numSubjects": "78"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "36"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "25"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "BG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "96"}, {"groupId": "BG001", "value": "114"}, {"groupId": "BG002", "value": "210"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.1", "spread": "10.2"}, {"groupId": "BG001", "value": "54.5", "spread": "10.8"}, {"groupId": "BG002", "value": "54.8", "spread": "10.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "63"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "79"}, {"groupId": "BG002", "value": "147"}]}]}]}, {"title": "Race (NIH/OMB)", "description": "Self-reported race. Since the participants were allowed to select more than one race, the sum of races is greater than the number of participants in each group.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "36"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "93"}, {"groupId": "BG002", "value": "169"}]}]}, {"title": "More than one race", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Unknown or Not Reported", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "New York Heart Association (NYHA) Classification", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "NYHA I: Pts w/cardiac disease, w/o activity limit", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}, {"title": "NYHA II; Pts w/cardiac disease, slight limits", "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "102"}]}]}, {"title": "NYHA III; Marked limit to physical activity", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "100"}]}]}, {"title": "NYHA IV; inability to have activity w/o discomfort", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Heart Failure Etiology", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Non-ischemic", "categories": [{"measurements": [{"groupId": "BG000", "value": "62"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "142"}]}]}, {"title": "Ischemic", "categories": [{"measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "68"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Duration of Heart Failure (time)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.7", "spread": "6.2"}, {"groupId": "BG001", "value": "6.5", "spread": "5.0"}, {"groupId": "BG002", "value": "7.1", "spread": "5.6"}]}]}]}, {"title": "Cardiac Medications", "description": "Baseline information for specific cardiac medications was requested. Since most participants were on more than one medication, the sum of medications are greater than the number of participants in each group.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "ACE Inhibitors", "categories": [{"measurements": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "158"}]}]}, {"title": "Antiogensin Receptor Blockers", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "51"}]}]}, {"title": "Beta Blockers", "categories": [{"measurements": [{"groupId": "BG000", "value": "94"}, {"groupId": "BG001", "value": "114"}, {"groupId": "BG002", "value": "208"}]}]}, {"title": "Diuretics (other than Spironolactone)", "categories": [{"measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "100"}, {"groupId": "BG002", "value": "181"}]}]}, {"title": "Aldosterone Inhibitors", "categories": [{"measurements": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "76"}, {"groupId": "BG002", "value": "129"}]}]}, {"title": "Digoxin", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "98"}]}]}]}, {"title": "Medical History and Co-Morbidities", "description": "Baseline information on specific co-morbities was requested. Since many participants had more than one co-morbidity, the sum of co-morbidities are greater than the number of participants in each group.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Systemic Hypertension", "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "102"}]}]}, {"title": "Pulmonary Hypertension", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "30"}]}]}, {"title": "Diabetes Mellitus", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "72"}]}]}, {"title": "Chronic Obstructive Pulmonary Disease (COPD)", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "21"}]}]}, {"title": "Sleep Apnea", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "58"}]}]}, {"title": "Asthma", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "22"}]}]}, {"title": "Coronary Artery Disease with Angioplasty/Stent", "categories": [{"measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "61"}]}]}, {"title": "Stroke TIA/Other Thromboembolic Events", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "21"}]}]}, {"title": "Peripheral Vascular Disease", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "4"}]}]}, {"title": "Myocardial Infarction", "categories": [{"measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "68"}]}]}, {"title": "Ventricular Tachycardia", "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "68"}]}]}, {"title": "Atrial Fibrillation", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "28"}, {"groupId": "BG002", "value": "50"}]}]}, {"title": "Biventricular Pacemaker", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}]}, {"title": "Biventricular ICD", "categories": [{"measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "98"}]}]}, {"title": "Pacemaker alone", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "ICD alone", "categories": [{"measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "87"}]}]}, {"title": "ICD with Bradycardia Pacing Capability", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Responder Analysis - Peak Oxygen Uptake (Peak VO2)", "description": "A participant was considered a \"responder\" if cardiopulmonary exercise testing demonstrated an improvement in peak VO2 of at least 1.0 ml/kg/min at 6 months as compared to baseline.", "populationDescription": "The population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "35"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis = proportion of subjects in treatment group who successfully achieved an improvement of at least 1.0 ml/kg/min at 6 months is less than or equal to the Control group. Subjects who withdrew for cardiac-related reasons were classified as non-responders.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.502", "statisticalMethod": "Fisher Exact", "statisticalComment": "One-sided"}]}, {"type": "PRIMARY", "title": "Responder Analysis - Six (6) Minute Walk (6MW) Distance", "description": "A participant was considered a \"responder\" if 6MW distance at 6 months was at least 45 meters more than at baseline.", "populationDescription": "The population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline to 6 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "87"}, {"groupId": "OG001", "value": "99"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "25"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null hypothesis = the proportion of subjects in the treatment group who successfully achieved an improvement of at least 45 m at 6 months from baseline is less than or equal to that of the Control group. Withdrawals due to cardiac reasons are counted as non-responders.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.044", "statisticalMethod": "Fisher Exact", "statisticalComment": "One-sided"}]}, {"type": "PRIMARY", "title": "Responder Analysis - Minnesota Living With Heart Failure (MLWHF) Quality of Life Overall Score", "description": "A participant was considered a \"responder\" if the MLHF overall score had improved by at least 7 points at 6 months as compared to baseline. THE MLHF questionnaire evaluates the impact of heart failure (HF) on a subject's physical, emotional, social and mental aspects of quality of life. Each of 21 questions about how much HF impacts daily activities is scored from 0-no impact to 5-very much (overall score can range from 0 to 105). Improvement is indicated by a decrease in score.", "populationDescription": "The population is intent to treat.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "baseline to 6 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "50"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null hypothesis = the proportion of treatment subjects who successfully achieved an improvement of at least 7 points at 6 months is equal to or less than that of the control group. Withdrawals due to cardiac reasons are counted as non-responders.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.184", "statisticalMethod": "Fisher Exact", "statisticalComment": "One-sided"}]}, {"type": "PRIMARY", "title": "Number of Participant Deaths", "description": "Total number of participants who died within 12 months of enrollment into the trial.", "populationDescription": "The population is intent to treat.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null hypothesis = survival in the treatment group at 12 months is not equivalent to that of the Control group.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Estimated survival for the treatment group was 93%. Estimated survival for the control group was 91.5%. A non-inferiority margin of 7.5%. Final test alpha level of 0.04825.", "pValue": "0.012", "statisticalMethod": "Exact binomial test", "statisticalComment": "One-sided"}]}, {"type": "SECONDARY", "title": "Change in New York Heart Association (NYHA) Functional Class", "description": "Change in NYHA functional class between baseline and 6 months. \"Maintained\" means the participant's functional class remained the same as baseline. \"Improved\" means the participant's functional class improved (became lower in number) by at least one class. \"Worsened\" means the participant's functional class deteriorated (became higher in number) by at least one class.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "baseline to 6 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "103"}]}], "classes": [{"title": "Improved", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "29"}]}]}, {"title": "Maintained", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "59"}]}]}, {"title": "Worsened", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Class change from baseline.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.052", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Change in Quality of Life as Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)", "description": "The KCCQ is a 23-item questionnaire that quantifies physical function, symptoms, social function, self-efficacy/knowledge and quality of life. Scores range from 0 to 100, where higher scores reflect better health status. For this outcome measure, the difference between each participant's baseline and 6-month KCCQ scores was calculated. The mean change for each treatment arm is presented.", "populationDescription": "Population is intent to treat", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on a scale", "timeFrame": "baseline to 6 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "99"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.6", "spread": "18.2"}, {"groupId": "OG001", "value": "3.4", "spread": "16.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "t-test, 2 sided"}]}, {"type": "SECONDARY", "title": "Change in Left Ventricular Mass", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular mass was calculated. The median change for each treatment arm is presented. A decrease in mass is associated with an improvement in the participant's structural heart failure.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "grams", "timeFrame": "baseline to 6 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "94"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-19.0", "lowerLimit": "-119.0", "upperLimit": "81.0"}, {"groupId": "OG001", "value": "7.0", "lowerLimit": "-254.0", "upperLimit": "109.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.032", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "statisticalComment": "Two-sided"}]}, {"type": "SECONDARY", "title": "Responder Analysis - Peak Oxygen Uptake (Peak VO2)", "description": "A participant was considered a \"responder\" if cardiopulmonary exercise testing demonstrated an improvement in peak VO2 of at least 1.0 ml/kg/min at 12 months as compared to baseline.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "baseline to 12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "21"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Improvement of at least 1.0 ml/kg/min from baseline.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.540", "statisticalMethod": "Fisher Exact", "statisticalComment": "One-sided"}]}, {"type": "SECONDARY", "title": "Responder Analysis - Six (6) Minute Walk (6MW) Distance", "description": "A participant was considered a \"responder\" if 6MW distance at 12 months was at least 45 meters more than at baseline.", "populationDescription": "Population is intent to treat", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "baseline to 12 Months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "90"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "25"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Improvement of at least 45 m from baseline.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.067", "statisticalMethod": "Fisher Exact", "statisticalComment": "One-sided"}]}, {"type": "SECONDARY", "title": "Responder Analysis - Minnesota Living With Heart Failure (MLWHF) Quality of Life Overall Score", "description": "A participant was considered a \"responder\" if the MLHF overall score had improved by at least 7 points at 12 months as compared to baseline. THE MLHF questionnaire evaluates the impact of heart failure (HF) on a subject's physical, emotional, social and mental aspects of quality of life. Each of 21 questions about how much HF impacts daily activities is scored from 0-no impact to 5-very much (overall score can range from 0 to 105). Improvement is indicated by a decrease in score.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "baseline to 12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "43"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Improvement of at least 7 points from baseline.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.031", "statisticalMethod": "Fisher Exact", "statisticalComment": "One-sided"}]}, {"type": "SECONDARY", "title": "Heart Failure Hospitalization - Actuarial Analysis", "description": "Kaplan-Meier actuarial analysis of heart failure hospitalization (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Kaplan-Meier actuarial time-to-first-event analysis", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.109", "statisticalMethod": "Log Rank"}]}, {"type": "SECONDARY", "title": "Change in Left Ventricular End Diastolic Volume", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end diastolic volume was calculated. The median change for each treatment arm is presented. A decrease in volume is associated with an improvement in the participant's structural heart failure.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "milliliters", "timeFrame": "baseline to 6 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.8", "lowerLimit": "-108.1", "upperLimit": "127.5"}, {"groupId": "OG001", "value": "10.9", "lowerLimit": "-143.7", "upperLimit": "176.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.031", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "statisticalComment": "Two-sided"}]}, {"type": "SECONDARY", "title": "Change in Left Ventricular End Systolic Volume", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end systolic volume was calculated. The median change for each treatment arm is presented. A decrease in volume indicates an improvement in the participant's structural heart failure.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "milliliters", "timeFrame": "baseline to 6 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.0", "lowerLimit": "-100.5", "upperLimit": "125.0"}, {"groupId": "OG001", "value": "2.75", "lowerLimit": "-134.2", "upperLimit": "150.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.179", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "statisticalComment": "Two-sided"}]}, {"type": "SECONDARY", "title": "Change in Ejection Fraction", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular ejection fraction was calculated. The median change for each treatment arm is presented.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "percent", "timeFrame": "baseline to 6 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "lowerLimit": "-11.0", "upperLimit": "16.0"}, {"groupId": "OG001", "value": "1.9", "lowerLimit": "-18.0", "upperLimit": "21.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.070", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "statisticalComment": "Two-sided"}]}, {"type": "SECONDARY", "title": "Change in Left Ventricular End Diastolic Diameter", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end diastolic diameter was calculated. The median change for each treatment arm is presented. A decrease in diameter indicates an improvement in the participant's structural heart failure.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "centimeters", "timeFrame": "baseline to 6 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "86"}, {"groupId": "OG001", "value": "99"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.15", "lowerLimit": "-1.2", "upperLimit": "1.7"}, {"groupId": "OG001", "value": "0", "lowerLimit": "-1.3", "upperLimit": "1.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.015", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "statisticalComment": "Two-sided"}]}, {"type": "SECONDARY", "title": "Change in Left Ventricular End Systolic Diameter", "description": "The difference between each participant's baseline and 6-month echocardiographic measure of left ventricular end systolic diameter was calculated. The median change for each treatment arm is presented. A decrease in diameter indicates an improvement in the participant's structural heart failure.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "centimeters", "timeFrame": "baseline to 6 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "85"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "lowerLimit": "-1.2", "upperLimit": "2.1"}, {"groupId": "OG001", "value": "0.1", "lowerLimit": "-1.8", "upperLimit": "1.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.032", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "statisticalComment": "Two-sided"}]}, {"type": "SECONDARY", "title": "Technical Success (Number of Treatment Arm Participants Successfully Implanted)", "description": "\"Technical success\" refers to the ability to successfully deliver a device onto the epicardial surface and leave the device in a satisfactory position. Participants who did not undergo an implant procedure were excluded from this analysis.", "populationDescription": "Population is as treated, treatment only.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "1 day", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "93"}, {"groupId": "OG001", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "92"}]}]}]}, {"type": "SECONDARY", "title": "Heart Failure Death", "description": "Number of participants who died within 12 months of enrolling in the study and whose cause of death was classified, by an independent Clinical Events Committee, as heart failure", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.627", "statisticalMethod": "Fisher Exact", "statisticalComment": "Two-sided"}]}, {"type": "SECONDARY", "title": "Heart Failure Death - Actuarial Analysis", "description": "Kaplan-Meier actuarial time-to-event analysis of deaths classified, by an independent Clinical Events Committee, as due to heart failure", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.386", "statisticalMethod": "Log Rank"}]}, {"type": "SECONDARY", "title": "Heart Failure Hospitalization", "description": "Number of participants who experienced a heart failure hospitaliz (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.154", "statisticalMethod": "Fisher Exact", "statisticalComment": "Two-sided"}]}, {"type": "SECONDARY", "title": "All-Cause Hospitalization", "description": "Number of participants who experienced a hospitalization (for any cause) within the first 12 months after enrollment. Within the Treatment Arm, hospitalization for the implant procedure was not included in this analysis.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "45"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "1.000", "statisticalMethod": "Fisher Exact", "statisticalComment": "Two-sided"}]}, {"type": "SECONDARY", "title": "All-Cause Hospitalization - Actuarial Analysis", "description": "Kaplan-Meier actuarial time-to-first-event analysis of all-cause hospitalizations", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "45"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.939", "statisticalMethod": "Log Rank"}]}, {"type": "SECONDARY", "title": "Participants Experiencing Serious Adverse Events", "description": "Number of participants who experienced a serious adverse event (as classified by an independent Clinical Events Committee) within the first 12 months after enrollment", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "47"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.012", "statisticalMethod": "Fisher Exact", "statisticalComment": "Two-sided"}]}, {"type": "SECONDARY", "title": "Serious Adverse Events - Actuarial Analysis", "description": "Kaplan-Meier actuarial time-to-first-event analysis of serious adverse events", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "47"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "Log Rank"}]}, {"type": "SECONDARY", "title": "Days Alive Out of Hospital", "description": "Median number of days participants were not hospitalized within the first 12 months after enrollment. Within the Treatment Arm, hospitalization for the implant procedure was not included in this analysis.", "populationDescription": "Population is intent to treat.", "reportingStatus": "POSTED", "anticipatedPostingDate": "2011-04", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "days", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy"}, {"id": "OG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "365", "lowerLimit": "45", "upperLimit": "365"}, {"groupId": "OG001", "value": "365", "lowerLimit": "149", "upperLimit": "365"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.772", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "statisticalComment": "Two-sided"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Participants were followed up to 3.5 years", "description": "Events adjudicated per Clinical Events Committee (CEC) Charter by independent CEC.", "eventGroups": [{"id": "EG000", "title": "Treatment", "description": "HeartNet and Optimal Medical/Device Therapy", "seriousNumAffected": 57, "seriousNumAtRisk": 96, "otherNumAffected": 85, "otherNumAtRisk": 96}, {"id": "EG001", "title": "Control", "description": "Optimal Medical/Device Therapy alone", "seriousNumAffected": 47, "seriousNumAtRisk": 114, "otherNumAffected": 71, "otherNumAtRisk": 114}], "seriousEvents": [{"term": "Worsening Heart Failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 42, "numAffected": 15, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 46, "numAffected": 27, "numAtRisk": 114}]}, {"term": "Non-Ischemic Atrial/Ventricular Dysrhythmia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 10, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 17, "numAffected": 11, "numAtRisk": 114}]}, {"term": "Cardiac Procedure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 12, "numAffected": 11, "numAtRisk": 114}]}, {"term": "Other Cardiac Hospitalization", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 12, "numAffected": 10, "numAtRisk": 114}]}, {"term": "Syncope", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 114}]}, {"term": "Myocardial Infarct", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 114}]}, {"term": "Coronary Insufficiency/Acute Coronary Syndrome/Unstable Angina", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Peripheral Vascular Disease", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Pulmonary or Vascular Emboli", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 114}]}, {"term": "Stroke", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Transient Ischemic Attack", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Non-cardiac vascular surgery", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Other Vascular Condition (nonspecific)", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Non-cardiac/Non-vascular", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Non-perioperative", "stats": [{"groupId": "EG000", "numEvents": 32, "numAffected": 22, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 36, "numAffected": 24, "numAtRisk": 114}]}, {"term": "Arrythmias", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Pericardial Syndrome", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Hypotension", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Blood Loss", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Worsening Heart Failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "LV Laceration", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Chest Pain Syndrome", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Stroke", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Renal Failure/Insufficiency", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Pleural Effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Prolonged Ventilation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Sleep Apnea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Bacteremia/Sepsis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Dehydration", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Anemia", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Gastroesophageal Reflux", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Gastrointestinal Bleeding", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Neuropathy", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Laryngeal Granuloma", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Ileus", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Alcohol Withdrawal", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Pulmonary Embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Perioperative, treatment only", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}], "otherEvents": [{"term": "Cardiovascular", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 117, "numAffected": 63, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 68, "numAffected": 46, "numAtRisk": 114}]}, {"term": "Respiratory/Pulmonary", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 38, "numAffected": 32, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 31, "numAffected": 22, "numAtRisk": 114}]}, {"term": "Gastrointestinal", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 7, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 11, "numAffected": 9, "numAtRisk": 114}]}, {"term": "Neurology", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 9, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 114}]}, {"term": "Renal", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 114}]}, {"term": "Hematology", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 114}]}, {"term": "Genital-urinary", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 4, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 114}]}, {"term": "General", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 97, "numAffected": 47, "numAtRisk": 96}, {"groupId": "EG001", "numEvents": 73, "numAffected": 35, "numAtRisk": 114}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "An interim analysis indicated trial futility based on a primary endpoint. Enrollment was suspended in July, 2009. Study was terminated as of April, 2011 due to insufficient resources."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Michael Kolber, General Manager, VP of Regulatory Affairs", "organization": "Paracor Medical, Inc.", "email": "info@paracor.com", "phone": "408-734-6000"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}